OncoMatch/Clinical Trials/NCT06884618
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Is NCT06884618 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies RO7673396 for neoplasms.
Treatment: RO7673396 — This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: KRAS mutation
Confirmed presence of the RAS mutation(s)
Required: NRAS mutation
Confirmed presence of the RAS mutation(s)
Required: HRAS mutation
Confirmed presence of the RAS mutation(s)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: within 4 weeks or five half-lives prior to initiation of study treatment
Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
Cannot have received: immunotherapy
Exception: within 4 weeks or five half-lives prior to initiation of study treatment
Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
Cannot have received: biologic therapy
Exception: within 4 weeks or five half-lives prior to initiation of study treatment
Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
Cannot have received: investigational agent
Exception: within 4 weeks or five half-lives prior to initiation of study treatment
Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate end-organ function
Liver function
adequate end-organ function
Adequate hematologic and end-organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- University of Colorado - Anschutz Medical Campus - PPDS · Aurora, Colorado
- Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
- Florida Cancer Specialists - Sarasota (North Catttlemen Rd) · Sarasota, Florida
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify